Market Overview

UPDATE: Piper Jaffray Upgrades Alnylam Pharmaceuticals to Overweight; Overhang Removed

Share:
Related ALNY
15 Biggest Mid-Day Losers For Wednesday
18 Biggest Mid-Day Gainers For Monday
Perceptive Advisors Llc Buys Alnylam Pharmaceuticals Inc, Global Blood Therapeutics Inc, ... (GuruFocus)

Piper Jaffray raised its rating on Alnylam Pharmaceuticals (NASDAQ: ALNY) from Neutral to Overweight and increased its price target from $19 to $25.

Piper Jaffray noted, "With the Tekmira litigation behind them, Alnylam can now focus on RNAi clinical progress and partnerships in 2013. Specifically, we look forward to Phase II ALN-TTR02 data this summer to prepare the company for pivotal studies by year-end. We also expect Alnylam to file INDs on sub-cutaneous formulations of ALN-TTR02 and ALN-AT3, an innovative hemophilia therapy. We also look for Alnylam to continue to partner its RNAi therapeutic pipeline, most importantly ALN-PCS to lower cholesterol."

Alnylam Pharmaceuticals closed at $17.99 on Tuesday.

Latest Ratings for ALNY

DateFirmActionFromTo
Apr 2017BMO CapitalInitiates Coverage OnOutperform
Mar 2017UBSInitiates Coverage OnNeutral
Feb 2017Ladenburg ThalmannInitiates Coverage OnBuy

View More Analyst Ratings for ALNY
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Upgrades Intraday Update Analyst Ratings

 

Related Articles (ALNY)

View Comments and Join the Discussion!